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Abstract
In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
issued an opinion on the safety and efﬁcacy of L-tryptophan produced by fermentation using three
strains of Escherichia coli, when used as a nutritional additive for all animal species. The
Panel concluded that the safety of L-tryptophan produced by E. coli SARI12091203 for target animals,
consumers, users and the environment could not be assessed because the data submitted did not
permit the identity and safety of the strain, and the purity of the additive, to be determined. During
the current assessment, the applicant withdrew the application for L-tryptophan produced by E. coli
SARI12091203. L-Tryptophan produced by E. coli DSM 25084 or KCCM 11132P was considered safe for
non-ruminant target species, the consumer and the environment. For both products, the level of
endotoxins and the possible dusting potential indicated a risk by inhalation for the user. In the absence
of data, a potential for dermal sensitisation could not be excluded. The Commission gave the applicant
the possibility of submitting complementary information to allow the FEEDAP Panel to complete its
assessment. The additional data on the characterisation of the additives and on their potential for
inhalation toxicity and as skin sensitisers are the subject of the current opinion. Due to improvements
in the manufacturing process, the level of endotoxins present in the L-tryptophan produced by E. coli
KCCM 11132P has been markedly reduced; consequently, the endotoxin content does not represent a
health risk for the user. The additive has a low acute toxicity by inhalation and is not considered as a
potential skin sensitiser. L-Tryptophan produced by E. coli DSM 25084 is not considered a skin
sensitiser. The level of endotoxins in this product, however, represents a risk by inhalation for the user
handling the additive.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety of
L-tryptophan produced by genetically modiﬁed strains of Escherichia coli (DSM 25084, KCCM 11132P or
SARI12091203) for all animal species. L-Tryptophan produced by E. coli SARI12091203 was withdrawn
from the application during the assessment.
The product under assessment is a nutritional feed additive produced by fermentation using one of
three strains of Escherichia coli. In 2015, the FEEDAP Panel issued an opinion on the safety and
efﬁcacy of the product and concluded that ‘L-Tryptophan produced by E. coli SARI12091203 could not
be assessed because the data submitted did not permit the identity and safety of the strain, and the
purity of the additive, to be determined. The EFSA Panel on Additives and Products or Substances
used in Animal Feed (FEEDAP) could not conclude on the safety of this product for target animals,
consumers, users and the environment’. L-Tryptophan produced by E. coli DSM 25084 or KCCM 11132P
was safe for non-ruminant target species when supplemented to diets in appropriate amount, for the
consumer of animal products and the environment. The FEEDAP Panel also concluded that ‘the level of
endotoxins present in the products of E. coli DSM 25084 or KCCM 11132P and its possible dusting
potential indicate an inhalation risk for the user. In the absence of data on the potential for dermal
sensitisation it is concluded that such potential may exist’.
The Commission gave the applicant the possibility of submitting complementary information to
allow the FEEDAP Panel to complete its assessment. The additional data on the characterisation of the
additives and on their potential for inhalation toxicity and as skin sensitisers are the subject of the
current opinion.
The EFSA FEEDAP Panel assessed the additional data using an approach in line with the principles
laid down in Regulation (EC) No 429/2008 and the relevant guidance documents: Guidance on
nutritional additives (EFSA FEEDAP Panel, 2012a) and Guidance on studies concerning the safety of
use of the additive for users/workers (EFSA FEEDAP Panel, 2012b).
Due to improvements in the manufacturing process, the level of endotoxins present in L-tryptophan
produced by E. coli KCCM 11132P has been markedly reduced; consequently, the endotoxin content
does not represent a health risk for the user. The additive has a low acute toxicity by inhalation and is
not considered as a potential skin sensitiser.
L-Tryptophan produced by E. coli DSM 25084 is not considered a skin sensitiser. The level of
endotoxins in this product, however, represents a risk by inhalation for the user handling the additive.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/20031 establishes rules governing the Community authorisation of
additives for animal nutrition and, in particular, article 9 deﬁnes the terms of the authorisation by the
Commission.
The applicant, AMAC/EEIG – Amino Acids Authorisation Consortium, is seeking a Community
authorisation of L-tryptophan, technically pure, to be used as nutritional additive for all animal species
(Table 1).
On September 2015, the Panel on Additives and Products or Substances used in Animal Feed of the
European Food Safety Authority (“Authority”), in its opinion on the safety and efﬁcacy of the product,
considers that L-Tryptophan produced by E. coli SARI12091203 could not be assessed because the
data submitted did not permit the identity and safety of the strain, and the purity of the additive, to be
determined. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
could not conclude on the safety of this product for target animals, consumers, users and the
environment. The level of endotoxins present in the products of E. coli KCCM 11132P or E. coli DSM
25084 and its possible dusting potential indicate an inhalation risk for the user. In the absence of data
on the potential for dermal sensitisation it is concluded that such potential may exist.
The Commission gave the possibility to the applicant to submit complementary information in order
to complete the assessment and to allow a revision of the Authority’s opinion.
On 15 July 2016 the Commission has received new data on L-tryptophan, technically pure. The
supplementary data are sent to the authority by the applicant.
In view of the above, the Commission asks the Authority to deliver a new opinion on L-tryptophan,
technically pure, produced by Escherichia coli strains DSM 25084, KCCM 11132P and SARI12091203 as
nutritional additive for all animal species based on the additional data submitted by the applicant.
1.2. Additional information
L-Tryptophan was ﬁrst authorised for use in animal nutrition by Directive 88/485/EEC. It is currently
authorised as a nutritional additive (functional group: amino acids, their salts and analogues) for use in
all animal species without time limit and without maximum content in feed.
The applicant has provided information on the endotoxin activity and dusting potential of the
product of E. coli DSM 25084, and information on endotoxin activity and studies on the safety for the
user of the product of E. coli KCCM 11132P. No information was received on strain SARI12091203 or
its product. During the assessment, however, the European Commission informed EFSA that the
applicant withdrew the application for the product of E. coli SARI12091203. In addition, the applicant
withdrew the use in water for drinking of the products of E. coli strains DSM 25084 and KCCM 11132P.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier2 following a previous application on the same product.3
Table 1: Description of the substances
Category of additive Nutritional additive
Functional group of additive Amino acids, their salts and analogues
Description L-tryptophan, technically pure
Target animal category All animal species
Applicant FEFANA
Type of request New opinion
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 FEED dossier reference: FAD-2016-0054.
3 FEED dossier reference: FAD-2010-0056.
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the characterisation and safety of
L-tryptophan produced by E. coli DSM 25084 and KCCM 11132P is in line with the principles laid down
in Regulation (EC) No 429/20084 and the relevant guidance documents: Guidance on nutritional
additives (EFSA FEEDAP Panel, 2012a) and Guidance on studies concerning the safety of use of the
additive for users/workers (EFSA FEEDAP Panel, 2012b).
3. Assessment
The current application is for the authorisation of L-tryptophan (minimum content of L-tryptophan
98% ‘as is’ basis) produced by two genetically modiﬁed (GM) strains of Escherichia coli (DSM 25084 or
KCCM 11132P). It is intended to be used in feed for all animal species as a nutritional additive
(functional group: amino acids, their salts and analogues).
In 2015, the FEEDAP Panel issued an opinion on the safety and efﬁcacy of L-tryptophan produced
by E. coli strains DSM 25084 or KCCM 11132P (EFSA FEEDAP Panel, 2015). The Panel concluded that
the additives produced by E. coli strains DSM 25084 and KCCM 11132P do not give rise to safety
concerns with regard to the genetic modiﬁcations of the production strain and that they are safe for
non-ruminant target species when supplemented to diets in nutritionally appropriate amount, but
should not be given to ruminants in an unprotected form because of the formation of skatole
(3-methylindole) during ruminal fermentation. The products of E. coli strains DSM 25084 and KCCM
11132P are also safe for the consumer of animal products and the environment. For both products,
the FEEDAP Panel expressed some concerns regarding safety for the user: ‘The level of endotoxins
present in the product and its possible dusting potential indicate an inhalation risk for the user. In the
absence of data on the potential for dermal sensitisation, it is concluded that such potential may
exist’.
The applicant has provided information on the endotoxin activity and the dusting potential of the
product of E. coli DSM 25084, and information on endotoxin activity and studies on the safety for the
user of the product of E. coli KCCM 11132P. These new data are the subject of the current opinion.
3.1. L-Tryptophan produced by Escherichia coli KCCM 11132P5
L-Tryptophan produced by E. coli KCCM 11132P has been characterised in a previous scientiﬁc
opinion (EFSA FEEDAP Panel, 2015).
The applicant stated that an improvement had been made in the production process to reduce the
amount of bacterial endotoxins in the ﬁnal product.6 To support this claim, additional data on the
content of endotoxins were submitted. Additionally, the applicant provided new toxicological studies to
support the safety for the user: an acute inhalation toxicity test and a skin sensitisation test.
3.1.1. Characterisation of the product
Before the change in the production process, the endotoxin activity (three batches) of the product
was up to 2,900 IU/mg.7 Three batches of the additive produced by the new method of production
were analysed for bacterial endotoxin activity. The values ranged from 0.09 to 0.29 IU/mg, showing a
reduction by four orders of magnitude of the upper endotoxin level compared to the former one of
2,900 IU/mg (European Pharmacopoeia 2.6.14 method D).8
Data on particle size and dusting potential were already assessed in the previous opinion. The
FEEDAP Panel considers that the changes in the manufacturing process would not signiﬁcantly affect
the physical properties of the additive. Particle size distribution analysis (one batch analysed by laser
diffraction (v/v)) showed that the percentages of particles below 100, 50 and 10 lm were about 90%,
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 This section has been amended following the applicable provisions on conﬁdentiality
6 Technical dossier/Supplementary information October 2016/Annex Qi Justif-Endotox reduced level CONFID.
7 Technical dossier FAD-2010-0056/Supplementary information May 2015/Annex Q1 Analysis of Microbial Endotoxins.
8 Technical dossier/endotoxin test results.
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67% and 17%, respectively.9 The dusting potential (Stauber–Heubach) measured in one batch was
2.5 g/m3.10
3.1.2. Safety for the user
3.1.2.1. Effects on the respiratory system
The changes in the manufacturing process made it necessary to reassess the relevance of the
bacterial endotoxin activities found in the ﬁnal product.
The scenario used to estimate the exposure of persons handling the additive to endotoxins in the
dust, based on the EFSA Guidance on user safety (2012b), is described in Appendix A. The health-
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU,
derived from provisional occupational exposure limits given by the Dutch Expert Committee on
Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the UK Health and Safety
Executive (HSE, 2013). Based upon the calculation of the potential endotoxin content in dust (Wallace
et al., 2016), the inhalation exposure could be up to 407 endotoxin IU per 8-h working day, indicating
no risk from the exposure to endotoxins for people handling the additive.
In an acute inhalation toxicity test (in accordance with OECD Guideline 403),11 a group of ﬁve
female and ﬁve male RccHan:WIST strain rats were exposed to dust of the additive under assessment
(98.5% purity) at a limit concentration of 5.1 g/m3 (60 L/min) for 4 h. After 14 days, the animals were
subject to necropsy. Treatment-related clinical abnormalities of the exposure to L-tryptophan consisted
of increased respiratory rate and hunched posture. All animals recovered within 4 days after exposure.
No macroscopic abnormalities were detected at necropsy. As mortality did not occur, the 4-h median
lethal concentration for L-tryptophan was estimated to be higher than 5.1 g/m3 for male and female
rats, indicating that the additive under assessment has a low acute toxicity by inhalation.
3.1.2.2. Effects on skin
A local lymph node assay (OECD Guideline 429) was conducted with the additive under assessment
(98.5% purity).12 The experiment comprised three L-tryptophan treatment groups (5%, 10% and 25%
L-tryptophan in a suspension in propylene glycol) of four female CBA/Ca mice each. No mortality
occurred during the study period; no systemic signs were observed. There were no signiﬁcant
differences between the L-tryptophan-treated groups and the vehicle control in the LLNA test. All
stimulation indexes were below a threefold increase in 3H-thymidine incorporation, the limiting value
required for the classiﬁcation as a skin sensitiser. The results indicate that the additive under
assessment is not a skin sensitiser.
3.1.3. Conclusions on the safety of L-tryptophan produced by Escherichia coli
KCCM 11132P for the users
Due to improvements in the manufacturing process, the endotoxin levels have been markedly
reduced; therefore, the endotoxin content of the additive under assessment does not represent a
health risk for the user. The results of an acute inhalation study indicate that the additive has a low
acute toxicity by this route. The additive is not considered as a potential skin sensitiser.
3.2. L-Tryptophan produced by Escherichia coli DSM 25084
L-Tryptophan produced by E. coli DSM 25084 has been characterised in a previous scientiﬁc opinion
(EFSA FEEDAP Panel, 2015).
The applicant stated that the production process has been further developed to decrease the
dusting potential of the additive. Additional data have been submitted on endotoxin activity and
dusting potential of the additive.
9 Technical dossier FAD-2010-0056/Supplementary information October 2014/Annexes Qi Particle size distribution.
10 Technical dossier FAD-2010-0056/Supplementary information October 2014/Annexes Qi Dusting Potential.
11 Technical dossier/acute inhalation toxicity.
12 Technical dossier/skin sensitisation.
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3.2.1. Characterisation of the product
The endotoxin activity in three batches of the product in the former application ranged from 23.9
to 31.6 IU/mg.13 New data have been submitted on the bacterial endotoxin activity of the product in
this application, measured in three batches. The values ranged from 0.18 to 0.34 IU/mg (European
Pharmacopoeia 2.6.14 method).14 The applicant, however, stated that no improvement had been
made in the production process to reduce the amount of bacterial endotoxins in the ﬁnal product and
that the reduction observed may be due to a ‘storage-dependent decrease’ attributable to the
absorption of endotoxins to the storage container (polypropylene).15 During the assessment the
applicant also stated that the endotoxin activity in the batches submitted could not be conﬁrmed and
that the previous results on endotoxin activity ranging from 23.9 to 31.6 IU/mg still represent the
status quo.15 Therefore, the FEEDAP Panel considers that the data representative for the endotoxin
activity of the L-tryptophan produced with E. coli DSM 25084 are those assessed in the former
scientiﬁc opinion (range 23.9–31.6 IU/mg).
The dusting potential (Stauber–Heubach) of three batches reported in the previous opinion ranged
from 2.3 to 2.9 g/m3.10 The applicant submitted data on three further batches which showed values
from 1.29 to 1.36 g/m3.16 The applicant stated that the reduction achieved was obtained through
process development, media optimisation and increased carbon source conversion of the fermentation
process, which lead to a purer product and resulted in larger particles during crystallisation.15
However, no new information on particle size distribution was provided.
3.2.2. Safety for the user
3.2.2.1. Effects on the respiratory system
Although a previous assessment was performed in January 2015 (EFSA FEEDAP Panel, 2015), the
technological change in the manufacturing process makes it necessary to reassess the relevance of the
bacterial endotoxin activities found in the ﬁnal product for the user.
The bacterial endotoxin activity ranges from 23.9 to 31.6 IU/mg (as in the previous submission; see
Section 3.2.1). The dusting potential ranges from 1.29 to 1.36 g/m3.
The scenario used to estimate the exposure of persons handling the additive to endotoxins in the
dust, based on the EFSA Guidance on user safety (2012b), is described in Appendix A. The health-
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU,
derived from provisional occupational exposure limits given by the DECOS (Health Council of the
Netherlands, 2010) and the UK Health and Safety Executive (HSE, 2013). Based upon the calculation
of the potential endotoxin content in dust (Wallace et al., 2016), the inhalation exposure could be up
to 23,900 (rounded ﬁgure) endotoxin IU per 8-h working day, which is over one magnitude order
greater than occupational exposure limit of 900 IU, indicating a risk from the exposure to endotoxins
for people handling the additive.
3.2.2.2. Effects on skin
No new information has been provided on the potential for dermal sensitisation of the product. The
FEEDAP Panel noted that additives under assessment differ only in the endotoxin content, which is not
considered to be relevant for skin sensitisation; otherwise, the two additives show similar physical
characteristics (particle size distribution) and the production strains share a common lineage (E. coli
K-12). Therefore, the FEEDAP Panel considers that the outcome of the dermal sensitisation study of
the product of E. coli KCCM 11132P can be extended to the product of E. coli DSM 25084.
3.2.3. Conclusions on the safety of L-tryptophan produced by Escherichia coli
DSM 25084 for the user
The level of endotoxins present in the product and its dusting potential indicate a health risk for the
user upon inhalation. The additive is not considered as a dermal sensitiser.
13 Technical dossier FAD-2010-0056/Supplementary information May 2015/Annexes Qi.
14 Technical dossier/endotoxins improvement.
15 Technical dossier/Supplementary information October 2016/Annex Qii Justif-Endotox reduced level.
16 Technical dossier/dusting potential.
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4. Conclusions
Due to improvements in the manufacturing process, the upper level of endotoxins present in
L-tryptophan produced by E. coli KCCM 11132P has been markedly reduced by four orders of
magnitude; consequently, the endotoxin does not represent a health risk for the user. The additive has
a low acute toxicity by inhalation and is not considered as a potential skin sensitiser.
L-Tryptophan produced by E. coli DSM 25084 is not considered a skin sensitiser. The level of
endotoxins in this product, however, represents a risk by inhalation for the user handling the additive.
Documentation provided to EFSA
1) L-Tryptophan produced by Escherichia coli for all animal species. September 2016. Submitted
by FEFANA Asbl.
2) L-Tryptophan produced by Escherichia coli for all animal species. Supplementary information.
October 2016. Submitted by FEFANA Asbl.
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Appendix A – Safety for the user of L-tryptophan produced by E. coli KCCM
11132P
Calculation of maximum acceptable levels of exposure from feed additives. The probable exposure
time according to EFSA guidance (EFSA FEEDAP Panel, 2012b) for additives added in premixtures
assumes a maximum of 40 periods of exposure per day, each comprising 20 s = 40 9 20 = 800 s/day.
With an uncertainty factor of 2, maximum inhalation exposure would occur for 2 9 800 =
1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h, the inhalation volume
providing exposure to potentially endotoxin-containing dust would be 0.444 9 1.25 = 0.556 m3/day.
This volume should contain no more than 900 IU endotoxin, so the dust formed from the product
should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust. Two key measurements are required to evaluate the
potential respiratory hazard associated with the endotoxin content of the product (the dusting potential
of the product, expressed in g/m3, and the endotoxin activity of the dust, determined by the Limulus
amoebocyte lysate assay (expressed in IU/g)). If data for the dust are not available, the content of
endotoxins of the product can be taken instead. If the content of endotoxins of the relevant additive is a
IU/g and the dusting potential is b g/m3, then the content of endotoxins of the dust, c IU/m3, is obtained
by simple multiplication, a 9 b. This resulting value is further used for calculation of the potential
inhalatory exposure of users to endotoxins from the additives under assessment (Tables A.1 and A.2)
(EFSA FEEDAP Panel, 2012b).
Table A.1: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli KCCM11132P, including consideration of using a ﬁlter mask FF P2 or FF
P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 293 Technical dossier
b Dusting potential (g/m3) 2.5 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 732.5
d No. of premixture batches made/
working day
40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
e Time of exposure (s) per production of
one batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
d 9 e f Total duration of daily exposure/worker
(s)
800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
f 9 g h Reﬁned total duration of daily
exposure/worker (s)
1,600
h/3,600 i Reﬁned total duration of daily exposure
(h)
0.44
j Inhaled air (m3) per 8-h working day 10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during
exposure per 8-h working day
407
m Health-based recommended exposure
limit of endotoxin (IU/m3) per 8-h
working day
90 Health Council of the
Netherlands (2010)
m 9 j n Health-based recommended
exposure limit of total endotoxin
exposure (IU) per 8-h working
day
900
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Calculation Identiﬁer Description Amount Source
l/10 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask FF
P2 (reduction factor 10)
41
l/20 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask FF
P3 (reduction factor 20)
20
Table A.2: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli DSM 25084, including consideration of using a ﬁlter mask FF P2 or FF P3
as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 31,600 Technical dossier
b Dusting potential (g/m3) 1.361 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 43,008
d No. of premixture batches made/
working day
40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
e Time of exposure (s) per production of
one batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
d 9 e f Total duration of daily exposure/worker
(s)
800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
f 9 g h Reﬁned total duration of daily
exposure/worker (s)
1,600
h/3,600 i Reﬁned total duration of daily exposure
(h)
0.44
j Inhaled air (m3) per 8-h working day 10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012b)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during
exposure per 8-h working day
23,893
m Health-based recommended exposure
limit of endotoxin (IU/m3) per 8-h
working day
90 Health Council of the
Netherlands (2010)
m 9 j n Health-based recommended
exposure limit of total endotoxin
exposure (IU) per 8-h working
day
900
l/10 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask FF
P2 (reduction factor 10)
2,389
l/20 Endotoxins inhaled (IU) per 8-h
working day reduced by ﬁlter mask FF
P3 (reduction factor 20)
1,195
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